Press "Enter" to skip to content

New patent expiration for Astrazeneca Pharms drug BRILINTA

0
Copyright © DrugPatentWatch. Originally published at New patent expiration for Astrazeneca Pharms drug BRILINTA

Annual Drug Patent Expirations for BRILINTA
Annual Drug Patent Expirations for BRILINTA

Brilinta is a drug marketed by Astrazeneca Pharms and is included in one NDA. It is available from two suppliers. There are six patents protecting this drug and two Paragraph IV challenges.

BRILINTA drug price trends.

Drug patent litigation for BRILINTA.

This drug has two hundred and twenty-nine patent family members in forty-eight countries.

The generic ingredient in BRILINTA is ticagrelor. Two suppliers are listed for this compound. Additional details are available on the ticagrelor profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Copyright © DrugPatentWatch. Originally published at New patent expiration for Astrazeneca Pharms drug BRILINTA
Do NOT follow this link or you will be banned from the site!